Sintilimab and anlotinib with gemcitabine plus cisplatin in advanced biliary tract cancer: SAGC a randomized phase 2 trial



Summary

The SAGC trial, a randomized phase 2 study, investigated the efficacy of sintilimab (a PD-1 inhibitor) and anlotinib (an anti-angiogenic) combined with gemcitabine plus cisplatin (GC) chemotherapy as first-line treatment for advanced biliary tract cancer (BTC). The study found that the sintilimab plus anlotinib with GC arm (SAGC) demonstrated a significantly improved objective response rate (ORR) and progression-free survival (PFS) compared to GC alone. While overall survival data is still maturing, the results suggest that adding sintilimab and anlotinib to standard chemotherapy may offer a promising new treatment option for patients with advanced BTC. Further research is needed to confirm these findings in larger phase 3 trials.

Read more…

This post is part of “Science/Immunology News”, Follow for more…!!!